香港2023年4月至2024年8月SARS-CoV-2疫苗对门诊就医SARS-CoV-2感染有效性估计:一项检测阴性设计研究
该研究采用检测阴性设计,纳入2023年4月至2024年8月香港5-64岁新发急性呼吸道疾病患者,评估6个月内接种SARS-CoV-2疫苗对实验室确诊感染的有效性。5-17岁组疫苗有效性为64%(95%CI:9-83%),18-64岁组为54%(95%CI:-39至77%),表明疫苗对儿童和成人门诊就医感染均有实质性保护。
要点
- 5-17岁组疫苗有效性64%(95%CI:9-83%),18-64岁组54%(95%CI:-39至77%)。
- 5-17岁组mRNA疫苗有效性85%(95%CI:32-97%),灭活疫苗59%(95%CI:2-83%),差异无统计学意义(p=0.33)。
- 有既往SARS-CoV-2感染史者疫苗有效性估计值更高。
核心结论
- SARS-CoV-2疫苗对香港儿童和成人门诊就医的SARS-CoV-2感染提供了实质性保护。
研究设计与样本
- 采用检测阴性设计,纳入2023年4月至2024年8月香港5-64岁、新发(≤3天)急性呼吸道疾病患者,接种定义为就医前6个月内接种SARS-CoV-2疫苗,敏感性分析为12个月内接种,按5-17岁和18-64岁分别用条件logistic回归调整潜在混杂因素估计疫苗有效性。
主要发现
- 5-17岁组疫苗有效性为64%(95%CI:9-83%),18-64岁组为54%(95%CI:-39至77%)。
- 5-17岁组mRNA疫苗有效性为85%(95%CI:32-97%),灭活疫苗为59%(95%CI:2-83%),两者差异无统计学意义(p=0.33)。
- 18-64岁组mRNA疫苗有效性为29%(95%CI:-81至73%),灭活疫苗为70%(95%CI:-5至92%),两者差异无统计学意义(p=0.38)。
- 有既往SARS-CoV-2感染史者疫苗有效性估计值高于无感染史者。
- 5-17岁组就医前自测SARS-CoV-2者疫苗有效性更高、未自测者更低,而18-64岁组观察到的模式相反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to estimate SARS-CoV-2 vaccine effectiveness (VE) against medically attended SARS-CoV-2 infection in Hong Kong. METHODS: We conducted a test-negative design study in individuals aged 5-64 years who presented with recent-onset (≤3 days) acute respiratory illness from April 2023 through to August 2024. Vaccination was defined as receipt of SARS-CoV-2 vaccine within 6 months of medical presentation, and for a sensitivity analysis, within 12 months of medical presentation. VE against laboratory-confirmed SARS-CoV-2 infection was estimated separately for 5-17-year-olds and 18-64-year-olds by conditional logistic regression adjusted for potential confounders. RESULTS: Within the age groups, there was no statistically significant difference in vaccination (within 6 months of medical presentation) proportions between cases and controls across strata of the assessed individual sociodemographic and health-related characteristics. A moderate VE of 64 % (95 % confidence interval, CI: 9-83 %) and 54 % (95 % CI: -39 to 77 %) was estimated in 5-17-year-olds and 18-64-year-olds, respectively. However, a higher VE of 85 % (95 % CI: 32-97 %) and a moderate VE of 59 % (95 % CI: 2-83 %) were estimated in 5-17-year-olds for mRNA and inactivated vaccines, respectively, although non-statistically significantly different (p = 0.33) whereas a lower VE of 29 % (95 % CI: -81 to 73 %) and a higher VE of 70 % (95 % CI: -5 to 92 %) were estimated in 18-64-year-olds for mRNA and inactivated vaccines, respectively, which were not statistically significantly different from each other (p = 0.38). VE estimates were higher for those who had had a previous SARS-CoV-2 infection compared with those who had not. VE was also higher in 5-17-year-olds who had self-tested for SARS-CoV-2 infection before medical presentation and lower in those who had not, whereas the opposite was observed in 18-64-year-olds. CONCLUSIONS: SARS-CoV-2 vaccines provided substantial protection against medically attended SARS-CoV-2 infection in both children and adults in Hong Kong.
引用
- Okoli GN, Murphy C, Mak L, et al. Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study. Vaccine. 2025. PMID: 40902334. doi:10.1016/j.vaccine.2025.127687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。